JP7689492B2 - 嚢胞性線維症を治療するためのアミノ酸組成物及び方法 - Google Patents
嚢胞性線維症を治療するためのアミノ酸組成物及び方法 Download PDFInfo
- Publication number
- JP7689492B2 JP7689492B2 JP2021523195A JP2021523195A JP7689492B2 JP 7689492 B2 JP7689492 B2 JP 7689492B2 JP 2021523195 A JP2021523195 A JP 2021523195A JP 2021523195 A JP2021523195 A JP 2021523195A JP 7689492 B2 JP7689492 B2 JP 7689492B2
- Authority
- JP
- Japan
- Prior art keywords
- cftr
- amino acids
- free amino
- amino acid
- proline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025087837A JP2025128185A (ja) | 2018-10-30 | 2025-05-27 | 喘息またはcopdを治療するためのアミノ酸組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752847P | 2018-10-30 | 2018-10-30 | |
| US62/752,847 | 2018-10-30 | ||
| PCT/US2019/058954 WO2020092639A1 (en) | 2018-10-30 | 2019-10-30 | Amino acid compositions and methods for treating cystic fibrosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087837A Division JP2025128185A (ja) | 2018-10-30 | 2025-05-27 | 喘息またはcopdを治療するためのアミノ酸組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506044A JP2022506044A (ja) | 2022-01-17 |
| JP2022506044A5 JP2022506044A5 (cg-RX-API-DMAC7.html) | 2022-11-09 |
| JP7689492B2 true JP7689492B2 (ja) | 2025-06-06 |
Family
ID=70464502
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523195A Active JP7689492B2 (ja) | 2018-10-30 | 2019-10-30 | 嚢胞性線維症を治療するためのアミノ酸組成物及び方法 |
| JP2025087837A Pending JP2025128185A (ja) | 2018-10-30 | 2025-05-27 | 喘息またはcopdを治療するためのアミノ酸組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025087837A Pending JP2025128185A (ja) | 2018-10-30 | 2025-05-27 | 喘息またはcopdを治療するためのアミノ酸組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12220400B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3873453A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7689492B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210086660A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164425B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019370363B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008395A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3116015A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005113A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020092639A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115697301A (zh) * | 2020-05-29 | 2023-02-03 | 佛罗里达大学研究基金会公司 | 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法 |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005501068A (ja) | 2001-08-08 | 2005-01-13 | プロフェッショナル・ダイエテティクス・ソシエタ・ア・レスポンサビリタ・リミタータ | 特に眼科分野における適用のための外傷および損傷の治癒および/または修復のための治療に適したアミノ酸組成物 |
| WO2009051909A1 (en) | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof |
| WO2009147637A1 (en) | 2008-06-06 | 2009-12-10 | Professional Dietetics S.R.L. | Compositions comprising amino acids, with pro-angiogenic activity |
| WO2016191263A1 (en) | 2015-05-22 | 2016-12-01 | Trustees Of Dartmouth College | Therapy and kit for the prevention and treatment of cystic fibrosis |
| WO2017223188A1 (en) | 2016-06-21 | 2017-12-28 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030224071A1 (en) * | 1999-08-20 | 2003-12-04 | Howard Murad | Pharmaceutical compositions and methods for managing connective tissue ailments |
| WO2002028348A2 (en) * | 2000-10-04 | 2002-04-11 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of cystic fibrosis |
| WO2002098405A1 (fr) * | 2001-06-05 | 2002-12-12 | Ajinomoto Co., Inc. | Inhibiteurs de fibrose du foie |
| EP1466602A4 (en) * | 2001-12-25 | 2006-03-01 | Ajinomoto Kk | ORGAN FIBROSIS INHIBITORS |
| NZ536796A (en) * | 2002-04-25 | 2007-03-30 | Scripps Research Inst | Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant |
| EP1513870A4 (en) * | 2002-05-31 | 2006-06-07 | Childrens Hosp Medical Center | CFTR MODIFIER GENES AND EXPRESSED POLYPEPTIDES SUITABLE FOR THE TREATMENT OF CYSTIC FIBROSIS AND METHOD AND PRODUCTS FOR DETECTING AND / OR IDENTIFYING THEM |
| AU2003901316A0 (en) * | 2003-03-21 | 2003-04-03 | The Royal Alexandra Hospital For Children | Regulation of cell surface proteins |
| US20040253319A1 (en) | 2003-06-11 | 2004-12-16 | Shrirang Netke | Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy |
| PT2664326T (pt) * | 2012-05-17 | 2018-01-19 | I E R F C European Institute For Cystic Fibrosis Res | Terapia combinada para a fibrose quística |
| US20140221424A1 (en) | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| MA41031A (fr) * | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| CN108463223A (zh) * | 2015-10-09 | 2018-08-28 | 艾伯维公司 | 用于治疗囊性纤维化的增效剂-校正剂组合 |
-
2019
- 2019-10-30 EP EP19879930.6A patent/EP3873453A4/en active Pending
- 2019-10-30 KR KR1020217015464A patent/KR20210086660A/ko not_active Ceased
- 2019-10-30 AU AU2019370363A patent/AU2019370363B2/en active Active
- 2019-10-30 MX MX2021005113A patent/MX2021005113A/es unknown
- 2019-10-30 CA CA3116015A patent/CA3116015A1/en active Pending
- 2019-10-30 US US17/289,374 patent/US12220400B2/en active Active
- 2019-10-30 BR BR112021008395-2A patent/BR112021008395A2/pt not_active Application Discontinuation
- 2019-10-30 JP JP2021523195A patent/JP7689492B2/ja active Active
- 2019-10-30 CN CN201980077878.6A patent/CN113164425B/zh active Active
- 2019-10-30 WO PCT/US2019/058954 patent/WO2020092639A1/en not_active Ceased
-
2025
- 2025-05-27 JP JP2025087837A patent/JP2025128185A/ja active Pending
- 2025-10-08 AU AU2025248660A patent/AU2025248660A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005501068A (ja) | 2001-08-08 | 2005-01-13 | プロフェッショナル・ダイエテティクス・ソシエタ・ア・レスポンサビリタ・リミタータ | 特に眼科分野における適用のための外傷および損傷の治癒および/または修復のための治療に適したアミノ酸組成物 |
| WO2009051909A1 (en) | 2007-10-16 | 2009-04-23 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr cellular processing and uses thereof |
| WO2009147637A1 (en) | 2008-06-06 | 2009-12-10 | Professional Dietetics S.R.L. | Compositions comprising amino acids, with pro-angiogenic activity |
| WO2016191263A1 (en) | 2015-05-22 | 2016-12-01 | Trustees Of Dartmouth College | Therapy and kit for the prevention and treatment of cystic fibrosis |
| WO2017223188A1 (en) | 2016-06-21 | 2017-12-28 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
Non-Patent Citations (1)
| Title |
|---|
| 医薬品インタビューフォーム アミパレン輸液,改訂第7版,2012年 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164425B (zh) | 2026-07-31 |
| BR112021008395A2 (pt) | 2021-09-28 |
| EP3873453A4 (en) | 2022-08-03 |
| US20210393584A1 (en) | 2021-12-23 |
| MX2021005113A (es) | 2021-06-15 |
| KR20210086660A (ko) | 2021-07-08 |
| US12220400B2 (en) | 2025-02-11 |
| AU2019370363B2 (en) | 2025-07-10 |
| CA3116015A1 (en) | 2020-05-07 |
| CN113164425A (zh) | 2021-07-23 |
| WO2020092639A1 (en) | 2020-05-07 |
| AU2025248660A1 (en) | 2025-10-30 |
| AU2019370363A1 (en) | 2021-05-13 |
| JP2022506044A (ja) | 2022-01-17 |
| JP2025128185A (ja) | 2025-09-02 |
| EP3873453A1 (en) | 2021-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025128185A (ja) | 喘息またはcopdを治療するためのアミノ酸組成物及び方法 | |
| Rotin et al. | Function and regulation of the epithelial Na+ channel ENaC | |
| US20250197463A1 (en) | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | |
| TWI870336B (zh) | 重組人類酸性α-葡萄糖苷酶 | |
| US20250032424A1 (en) | Lipid nanoparticle compositions and uses thereof | |
| US20020115619A1 (en) | Compositions and methods for treatment of cystic fibrosis | |
| JP6672139B2 (ja) | 粘液の粘性の正常化のための組成物 | |
| JPWO2002002135A1 (ja) | 脱髄疾患の予防及び治療薬 | |
| EP4003397B1 (en) | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr | |
| WO1996006612A1 (en) | Method and composition for treating cystic fibrosis | |
| WO2020115231A1 (en) | Methods and compositions for treating cystic fibrosis airways | |
| WO2019070759A1 (en) | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS | |
| Schwiebert et al. | Cystic fibrosis: a multiple exocrinopathy caused by dysfunctions in a multifunctional transport protein | |
| US20070213261A1 (en) | Asthma Preparation | |
| RS63070B1 (sr) | Kompozicije i postupci za upotrebu u lečenju homocistinurije | |
| EP2665485B1 (en) | Apolipoprotein aiv as an antidiabetic peptide | |
| Wu et al. | CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways | |
| EP3452041B1 (en) | Compositions and methods for administering ppar-gamma-agonists, surfactant peptides and phospholipids | |
| WO2019070753A1 (en) | AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA | |
| Tomich et al. | Channel replacement therapy for cystic fibrosis | |
| US20210038575A1 (en) | Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis | |
| JP7630540B2 (ja) | 神経保護ペプチド | |
| WO2018106918A1 (en) | Neuronal survival and axonal regeneration through increasing mitochondrial motility | |
| US20250255934A1 (en) | Compositions for treating inflammatory airway disease and uses thereof | |
| US5834421A (en) | Methods and compositions for treating cystic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210802 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221028 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240502 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240903 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20241128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250428 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250527 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7689492 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |